Susan Estrella-Eades
Family · Philadelphia, PANPI 1821334376
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,325 of the $61,475 with a category attached, or 80.2%. AstraZeneca accounts for 95.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $36,655 and has fallen 99.4% since, to $238 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $391.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$59K
- Amgen$1K
- Boehringer Ingelheim$447
- Bayer$200
- Gilead$128
- Regeneron Healthcare Solutions, Inc.$122
- plus $379 from 9 others
What the payments were for
- Consulting fees$1,8853%
- Speaking & faculty fees$49,32580%
- Travel & lodging$5,1588%
- Food & beverage$5,1078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 135 | $58,910 |
| Amgen | 5 | $1,290 |
| Boehringer Ingelheim | 2 | $447 |
| Bayer | 1 | $200 |
| Gilead | 1 | $128 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Inspire Medical Systems, Inc. | 1 | $107 |
| Cipher Pharmaceuticals US LLC | 1 | $55 |
| Coloplast | 1 | $55 |
| Electromed, Inc. | 3 | $44 |
| Boston Scientific | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,475 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $809 |
Paid to pharmacies, not to this prescriber.
Other family in Philadelphia
- Bethany ThomasPhiladelphia$126K
- Anne CalvaresiPhiladelphia$81K
- Bethany MooneyPhiladelphia$73K
- Michelle Vega-OlivoPhiladelphia$55K
- Danielle LandPhiladelphia$48K
- Nicole SmithPhiladelphia$37K
- Dana SerafinPhiladelphia$31K
- Tammaris KaschakPhiladelphia$27K
- Laura NoltePhiladelphia$21K
- Christopher RenziPhiladelphia$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.